Early Cardiac Inflammation As a Driver of Murine Model of Arrhythmogenic Cardiomyopathy

Total Page:16

File Type:pdf, Size:1020Kb

Early Cardiac Inflammation As a Driver of Murine Model of Arrhythmogenic Cardiomyopathy bioRxiv preprint doi: https://doi.org/10.1101/2020.06.24.169664; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Early cardiac inflammation as a driver of murine model of Arrhythmogenic Cardiomyopathy K.E. Ng1,2, P.J. Delaney2, D. Thenet2, S. Murtough2, C.M.Webb2, E.Tsisanova1, S.L.M Walker1, J.D. Westaby4, D.J Pennington2, R.Pink3, D.P. Kelsell2* & A. Tinker1* 1William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. 2Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, UK. 3Department of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP. 4CRY Dept. of Cardiovascular Pathology, Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, Jenner Wing, St. George’s University of London, Cranmer Terrace, London,SW17 0RE. *Joint senior and corresponding authors: Professor Andrew Tinker E-mail: [email protected] and Professor David Kelsell E-mail: [email protected] Running title: Desmoglein 2 and cardiac inflammation Keywords:, Desmoglein 2 (Dsg2), arrhythmogenic cardiomyopathy (AC), desmosome, cardiac inflammation, macrophages, fibrosis, rhomboid family member 2 (iRHOM2) , ADAM metallopeptidase domain 17 (Adam17/TACE), tumor necrosis factor alpha (TNFα), interleukin-6 (Il-6), RNA-Sequencing (RNA-Seq). 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.24.169664; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract: Both may present with prominent extracardiac features involving the skin (Palmoplantar The study of a desmoglein 2 murine model of keratoderma) and/or woolly hair. The genetic arrhythmogenic cardiomyopathy revealed cardiac basis for the disease was first revealed by the inflammation as a key early event leading to study of autosomal recessive forms of the fibrosis. Arrhythmogenic Cardiomyopathy (AC) cardiocutaneous form of AC and demonstrated is an inherited heart muscle disorder leading to loss of function mutations in desmoplakin ventricular arrhythmias and heart failure due to (Carvajal syndrome) and plakoglobin (Naxos abnormalities in the cardiac desmosome. We disease) (3, 4). Both of these genes encode examined how loss of desmoglein 2 (Dsg2) in the proteins that are part of the desmosome. This young murine heart leads to development of AC. prompted studies in autosomal dominant AC Cardiomyocyte apoptosis was an early cellular including the examination of other desmosomal phenotype and RNA-Seq analysis revealed early genes and revealed mutations in other activation of inflammatory-associated pathways components of the cardiac desmosome including in Dsg2 null (Dsg2-/-) hearts at postnatal day 14 desmoglein (DSG2), desmocollin2 (DSC2) and (Two weeks) that were absent in the fibrotic heart plakophilin2 (PKP2) (5-7). Desmosomes tether of adult mice (Ten weeks). This included cardiomyocytes together by linking cells at the upregulation of iRhom2/ADAM17 and its intercalated disc with the intermediate filaments, associated pro-inflammatory cytokines and specifically desmin, in the cytoskeleton (8). receptors such as TNFα, IL6R and IL-6. Together with gap junctions and adherens Furthermore, genes linked to specific junctions in the area composita of the intercalated macrophage populations were upregulated. This disc; they provide mechanical and electrical suggests cardiomyocyte stress triggers an early connection between cells (9). immune response to clear apoptotic cells AC can be a largely asymptomatic allowing tissue remodelling later on in the fibrotic dormant condition until the initial cardiac episode heart. Our analysis at different disease stages occurs in later life. These disease triggers implicate inflammation related to loss of underlying AC are still largely unknown though desmoglein 2 as a major mechanism for disease exercise and/or infection are proposed external progression. factors with desmosomal dysregulation and cell adhesion as likely consequences. Early Introduction: observations from myocarditis patient biopsies previously suggested the involvement of a Arrhythmogenic cardiomyopathy (AC), also systemic viral trigger however; no research has referred to as arrhythmogenic right ventricular been able to confirm this as the cause (10-13). cardiomyopathy (ARVC), is an inherited heart Interestingly, subsequent studies described the muscle disease characterised by ventricular presence of inflammatory infiltrates in post arrhythmias notably ventricular tachycardia and mortem biopsies from patients with AC (13). fibrillation and later in the disease process heart Interestingly, clinical reports of myocarditis in failure (1, 2). It is often a cause of cardiac arrest recent paediatric cases highlight the connection in young athletes. The condition appears to have between inflammation and AC (14). The acute arrhythmogenic phases before a decline in examination of the early cardiac development in ventricular function that occurs later in the murine models of AC may provide further insight disease. Pathologically it is characterised by to the mechanisms that link the loss of cardiac chamber dilatation and fibrofatty desmoglein 2 and the inflammatory response. replacement of myocytes. Historically, it was There are a number of murine models for thought to be a predominantly a right ventricular AC, including those involving genetic disease but biventricular and left ventricular manipulation of Dsg2 (15-20), that have been patterns are now widely recognised (1, 2). The developed and studied. Global genetic deletion of disease is hereditary in origin occurring in about Dsg2 is embryonically lethal whilst 1 in 5,000 births and is generally autosomal heterozygotes with haplo-insufficiency appear dominant though recessive forms are recognised. normal (17). In contrast, transgenic mice 2 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.24.169664; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. overexpressing a missense dsg2 mutation or a response has not been examined in detail in these knock-in mouse lacking a domain of Dsg2 transgenic mice. We hypothesized the immune develop cardiac dysfunction similar to that seen response and stress pathways in the weeks in AC (15, 18). AC can be characterised by acute following birth may play a larger role in the episodes of worsening pathology punctuating a immediate stages of the disease than initially more stable disease course (1). In this study, we reported (19). We studied the identity of this examine mice with the cardiac specific deletion inflammatory infiltrate at two weeks of age and of Dsg2 (19). We describe experimental evidence how inflammation may be associated with the and identify an early inflammatory response to progressive changes that lead to cardiac cardiomyocyte apoptosis that leads to cardiac dysfunction in the adult mouse (Ten weeks). fibrosis over time. Adult Dsg2-/- hearts exhibit fibrosis whereas Results: adult Dsg2+/+ and Dsg2+/- hearts appear morphologically similar Mice harbouring the tm1c allele for the Dsg2 gene (Supporting Figure S1A) were crossed with We first examined this murine model of AC by the alpha MHC Cre mice (21) and then bred to a directly comparing three groups: Dsg2 WT second generation to give the study cohort: Cre+, (Dsg2+/+), heterozygous (Dsg2+/-) and knockout Dsg2flx\flx (Dsg2-/-) or Dsg2flx\flx (Dsg2+/+) mice. (Dsg2-/-) mice at ten weeks (Figure 1). The results from morphometric analysis showed Histological analysis with i) Haematoxylin and no differences between the adult Dsg2+/+ and Eosin and ii) Trichrome stain revealed prominent Dsg2-/- groups (Supporting Figure S1B). We also structural differences between Dsg2+/+ and Dsg2- generated a small cohort of heterozygous mice /- hearts (Figure 1A). The changes in the Dsg2-/- (Dsg2+/-) to examine cardiac function and the heart were pronounced at adulthood with effect of gene dosage in AC disease development evidence of myocyte death and interstitial fibrosis (20). Most studies to date have characterised this i), collagen deposits ii) and in some severe cases, murine model therefore, we initially focused on calcification which appear as dark purple deposits recapitulating this information. DAB staining, within the fibrotic area. No abnormal RNA-Seq and qPCR confirmed substantial morphological changes or signs of fibrosis were decreases in transcripts translated into protein for observed in the Dsg2+/+ and Dsg2+/- hearts. Dsg2 (Supporting Figure 1C). The short axis The echocardiographic assessments from view of Dsg2 +/+ and Dsg2-/- hearts shows two the three genotypes are shown in Figure 1B. We morphologically different hearts at ten weeks of measured cardiac function in younger juvenile age. At post-mortem, the majority of Dsg2-/- mice (Six weeks) and adult mice (Ten weeks). hearts showed chamber dilatation in the left The heterozygous group were also included in the ventricle and sometimes right ventricle. Some analysis to reveal if the decline
Recommended publications
  • FLNC Missense Variants in Familial Noncompaction Cardiomyopathy
    Cardiogenetics 2019; volume 9:8181 FLNC missense variants than 2 according to current echocardio- in familial noncompaction graphic criteria, or 2.3 on CMR.1,2 Correspondence: Jaap I. van Waning, Approximately 10% of patients diagnosed Department of Clinical Genetics, EE 2038, cardiomyopathy with NCCM have concurrent congenital Erasmus MC, POB 2040, 3000CA Rotterdam, heart defects (CHD).3,4 the Netherlands. Tel.: +3107038388 - Fax: +3107043072. Jaap I. van Waning,1 In 30-40% of cases diagnosed with E-mail: [email protected] Yvonne M. Hoedemaekers,2 NCCM a pathogenic variant can be identi- 2,3 4 Wouter P. te Rijdt, Arne I. Jpma, fied. Around 80% of these pathogenic vari- Acknowledgements: JVW was supported by a Daphne Heijsman,4 Kadir Caliskan,5 ants involve the same sarcomere genes, that grant from the Jaap Schouten Foundation. Elke S. Hoendermis,6 are the major causes for hypertrophic car- WPTR was supported by a Young Talent Program (CVON PREDICT) grant 2017T001 Tineke P. Willems,7 diomyopathy (HCM) and dilated cardiomy- - Dutch Heart Foundation. 8 opathy (DCM), in particular MYH7, Arthur van den Wijngaard, 5,6 3 MYBPC3 and TTN. Filamin C (FLNC) Albert Suurmeijer, Conflict of interest: the authors declare no plays a central role in muscle functioning Marjon A. van Slegtenhorst,1 potential conflict of interest. by maintaining the structural integrity of the Jan D.H. Jongbloed,2 muscle fibers. Pathogenic variants in FLNC Received for publication: 20 March 2019. Danielle F. Majoor-Krakauer,1 2 were found to be associated with a wide Revision received: 29 July 2019. Paul A.
    [Show full text]
  • Genetic Mutations and Mechanisms in Dilated Cardiomyopathy
    Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, … , Jessica R. Golbus, Megan J. Puckelwartz J Clin Invest. 2013;123(1):19-26. https://doi.org/10.1172/JCI62862. Review Series Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of congestive heart failure. In hypertrophic cardiomyopathy (HCM), cardiac output is limited by the thickened myocardium through impaired filling and outflow. Mutations in the genes encoding the thick filament components myosin heavy chain and myosin binding protein C (MYH7 and MYBPC3) together explain 75% of inherited HCMs, leading to the observation that HCM is a disease of the sarcomere. Many mutations are “private” or rare variants, often unique to families. In contrast, dilated cardiomyopathy (DCM) is far more genetically heterogeneous, with mutations in genes encoding cytoskeletal, nucleoskeletal, mitochondrial, and calcium-handling proteins. DCM is characterized by enlarged ventricular dimensions and impaired systolic and diastolic function. Private mutations account for most DCMs, with few hotspots or recurring mutations. More than 50 single genes are linked to inherited DCM, including many genes that also link to HCM. Relatively few clinical clues guide the diagnosis of inherited DCM, but emerging evidence supports the use of genetic testing to identify those patients at risk for faster disease progression, congestive heart failure, and arrhythmia. Find the latest version: https://jci.me/62862/pdf Review series Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, Jessica R. Golbus, and Megan J. Puckelwartz Department of Human Genetics, University of Chicago, Chicago, Illinois, USA. Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of conges- tive heart failure.
    [Show full text]
  • A Rare Missense Mutation in MYH6 Confers High Risk of Coarctation of the Aorta
    bioRxiv preprint doi: https://doi.org/10.1101/180794; this version posted August 29, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A rare missense mutation in MYH6 confers high risk of coarctation of the aorta Thorsteinn Bjornsson1,12, Rosa B. Thorolfsdottir1,12, Gardar Sveinbjornsson1, Patrick Sulem1, Gudmundur L. Norddahl1, Anna Helgadottir1, Solveig Gretarsdottir1, Audur Magnusdottir1, Ragnar Danielsen2, Emil L. Sigurdsson3,4, Berglind Adalsteinsdottir5,6, Sverrir I. Gunnarsson7, Ingileif Jonsdottir1,6,8, David O. Arnar2,6, Hrodmar Helgason9, Tomas Gudbjartsson6,10, Daniel F. Gudbjartsson1,11, Unnur Thorsteinsdottir1,6, Hilma Holm1, Kari Stefansson1,6 1deCODE genetics/Amgen, Inc., Reykjavik, Iceland. 2Department of Medicine, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland. 3Department of Family Medicine, University of Iceland, Reykjavik, Iceland. 4Department of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland. 5Department of Cardiology, Haukeland University Hospital, Bergen, Norway 6Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 7Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin, Madison, WI, USA. 8Department of Immunology, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland. 9Children's Hospital, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland. 10Department of Cardiothoracic Surgery, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland. 11School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland. 12These authors contributed equally to this work. 1 bioRxiv preprint doi: https://doi.org/10.1101/180794; this version posted August 29, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research
    Cutting-Edge Review A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research Joseph M. Miano, Qiuyu Martin Zhu, Charles J. Lowenstein Abstract—Previous efforts to target the mouse genome for the addition, subtraction, or substitution of biologically informative sequences required complex vector design and a series of arduous steps only a handful of laboratories could master. The facile and inexpensive clustered regularly interspaced short palindromic repeats (CRISPR) method has now superseded traditional means of genome modification such that virtually any laboratory can quickly assemble reagents for developing new mouse models for cardiovascular research. Here, we briefly review the history of CRISPR in prokaryotes, highlighting major discoveries leading to its formulation for genome modification in the animal kingdom. Core components of CRISPR technology are reviewed and updated. Practical pointers for 2-component and 3-component CRISPR editing are summarized with many applications in mice including frameshift mutations, deletion of enhancers and noncoding genes, nucleotide substitution of protein-coding and gene regulatory sequences, incorporation of loxP sites for conditional gene inactivation, and epitope tag integration. Genotyping strategies are presented and topics of genetic mosaicism and inadvertent targeting discussed. Finally, clinical applications and ethical considerations are addressed as the biomedical community eagerly embraces this astonishing innovation in genome editing to tackle previously
    [Show full text]
  • SUPPLEMENTAL MATERIAL Data S1
    SUPPLEMENTAL MATERIAL Data S1. Supplementary Methods: Methods Fasting studies in mice: Mice were housed in groups of up to n = 5 mice/cage and fed standard chow (Lab Diet, 5053; providing 3.4 Kcal/g with 62.1% Kcal derived from carbohydrates, 13.2% from fats, and 24.6% from protein) on a 6:00 PM to 6:00 AM dark-light cycle. Intermittent fasting was performed with total food deprivation and ad libitum access to water while mice were housed on a cedar pine chip bedding from 12:00 PM to 12:00 PM of the following day to implement alternate periods of 24 h fasting and feeding, with change in bedding (AL indicates fed ad libitum and IF indicates that animals were provided access to food every other day).1 Non-fasted control mice were simultaneously provided fresh food with change in bedding. Terminal studies on mice were initiated between 8:00 to 10:00 AM after an overnight period of feeding (i.e., on a fed day). For fasting studies to determine the effects on HSPB8 transcript levels in the heart, mice were fasted for various durations beginning at 6:00 PM (the onset of the dark cycle during which mice typically feed). Echocardiography: Echocardiography was performed using a Vevo 2100 Imaging System (VisualSonics, Toronto, Canada) equipped with a 30 MHz linear-array transducer according slight modifications of previously published methods.2, 3 Briefly, mice were anesthetized using 0.1 g/kg IP Avertin (2,2,2- Tribromoethanol, Sigma-Aldrich, St. Louis, MO). Cardiac images were obtained by a handheld technique.
    [Show full text]
  • Catenin Regulates Cardiac Energy Metabolism in Sedentary and Trained Mice
    life Article β-Catenin Regulates Cardiac Energy Metabolism in Sedentary and Trained Mice Volodymyr V. Balatskyi 1,2, Oksana L. Palchevska 1,3 , Lina Bortnichuk 1, Ana-Maria Gan 2, Anna Myronova 1, Larysa L. Macewicz 1, Viktor O. Navrulin 2, Lesya V. Tumanovska 4, Adam Olichwier 2, Pawel Dobrzyn 2,* and Oksana O. Piven 1,* 1 Department of Human Genetics, Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 150 Akademika Zabolotnogo Street, 03680 Kyiv, Ukraine; [email protected] (V.V.B.); [email protected] (O.L.P.); [email protected] (L.B.); [email protected] (A.M.); [email protected] (L.L.M.) 2 Laboratory of Molecular Medical Biochemistry, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland; [email protected] (A.-M.G.); [email protected] (V.O.N.); [email protected] (A.O.) 3 Laboratory of Neurodegeneration, International Institute of Molecular and Cell Biology in Warsaw, 46-580 Warsaw, Poland 4 Department of General and Molecular Pathophysiology, Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, 4 Bogomoletz Street, 01024 Kyiv, Ukraine; [email protected] * Correspondence: [email protected] (P.D.); [email protected] (O.O.P.); Tel.: +48-022-589-24-59 (P.D.); +38-044-526-07-39 (O.O.P.); Fax: +48-022-822-53-42 (P.D.); +38-044-526-07-59 (O.O.P.) Received: 15 November 2020; Accepted: 16 December 2020; Published: 17 December 2020 Abstract: The role of canonical Wnt signaling in metabolic regulation and development of physiological cardiac hypertrophy remains largely unknown.
    [Show full text]
  • Towards Development of a Statistical Framework to Evaluate Myotonic Dystrophy Type 1 Mrna Biomarkers in the Context of a Clinical Trial
    bioRxiv preprint doi: https://doi.org/10.1101/728881; this version posted August 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial Adam Kurkiewicz1*, Anneli Cooper3¤, Emily McIlwaine3, Sarah A. Cumming3, Berit Adam3, Ralf Krahe4, Jack Puymirat5, Benedikt Schoser6, Lubov Timchenko7, Tetsuo Ashizawa 8, Charles Thornton 9, Simon Rogers2Y, John McClure1Y, Darren G Monckton3Y 1 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom 2 School of Computing Science, University of Glasgow, Glasgow, United Kingdom 3 Institute of Molecular Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom 4 Department of Genetics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA 5 Laboratory of Human Genetics, CHUL Medical Research Centre, University of Laval, Quebec City, QC, Canada 6 Friedrich Baur Institute, Department of Neurology, Ludwig Maximilians University, Munich, Germany 7 Department of Pediatrics, Division of Neurology, Cincinnati Children's Hosptial, University of Cincinnati, College of Medicine, Cincinnati Ohio, USA 8 VA Medical Center, Houston, Texas, USA 9 University of Rochester, Medical Center School of Medicine and Dentistry, Rochester, New York, USA YThese authors contributed equally to this work. ¤Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United Kingdom * [email protected] August 7, 2019 1/28 bioRxiv preprint doi: https://doi.org/10.1101/728881; this version posted August 8, 2019.
    [Show full text]
  • Use of Biotinylated Ubiquitin for Analysis of Rat Brain Mitochondrial Proteome and Interactome
    Int. J. Mol. Sci. 2012, 13, 11593-11609; doi:10.3390/ijms130911593 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Use of Biotinylated Ubiquitin for Analysis of Rat Brain Mitochondrial Proteome and Interactome Olga A. Buneeva 1, Marina V. Medvedeva 2, Arthur T. Kopylov 1, Victor G. Zgoda 1 and Alexei E. Medvedev 1,* 1 Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, 10 Pogodinskaya street, Moscow 119121, Russia; E-Mails: [email protected] (O.A.B.); [email protected] (A.T.K.); [email protected] (V.G.Z.) 2 Moscow State University, Moscow, 119991, Russia; E-Mail: [email protected] (M.V.M.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +7-4992450509; Fax: +7-4992450857. Received: 27 July 2012; in revised form: 22 August 2012 / Accepted: 3 September 2012 / Published: 14 September 2012 Abstract: Applicability of in vitro biotinylated ubiquitin for evaluation of endogenous ubiquitin conjugation and analysis of ubiquitin-associated protein-protein interactions has been investigated. Incubation of rat brain mitochondria with biotinylated ubiquitin followed by affinity chromatography on avidin-agarose, intensive washing, tryptic digestion of proteins bound to the affinity sorbent and their mass spectrometry analysis resulted in reliable identification of 50 proteins belonging to mitochondrial and extramitochondrial compartments. Since all these proteins were bound to avidin-agarose only after preincubation of the mitochondrial fraction with biotinylated ubiquitin, they could therefore be referred to as specifically bound proteins. A search for specific ubiquitination signature masses revealed several extramitochondrial and intramitochondrial ubiquitinated proteins representing about 20% of total number of proteins bound to avidin-agarose.
    [Show full text]
  • Microrna-223 Prevents Cardiomyocyte Hypertrophy by Targeting Cardiac Troponin I-Interacting Kinase
    Abstracts Heart: first published as 10.1136/heartjnl-2011-300867.142 on 12 October 2011. Downloaded from http://heart.bmj.com/ on September 25, 2021 by guest. Protected copyright. [gw22-e0092] MICRORNA-223 PREVENTS CARDIOMYOCYTE HYPERTROPHY BY TARGETING CARDIAC TROPONIN I-INTERACTING KINASE Wang Yaosheng, Cheng Xiaoshu, Hong Kui, Wu Yanqing, Wu Qinghua, Su Hai Department Of Cardiology, Second Affiliated Hospital To Nanchang University, Nanchang, China 10.1136/heartjnl-2011-300867.142 Objectives Our study was designed to investigate the role of microRNA-223 (miR-223) and its direct target gene, cardiac troponin I-interacting kinase (TNNI3K), in regulating cardio- myocyte hypertrophy. Methodology Neonatal rat cardiomyocytes (CMs) were cultured from one to two days old Sprague–Dawley rats. Cardiomyocyte hypertrophy was induced by endothelin-1 Heart October 2011 Vol 97 No 21 Suppl 3 A49 Heartnjl.indd Sec1:49 9/23/2011 3:26:51 PM Abstracts Heart: first published as 10.1136/heartjnl-2011-300867.142 on 12 October 2011. Downloaded from (ET-1). Expression of miR-223 in CMs was detected by real- time PCR. miR-223 mimics transfection was performed to achieve overexpression of miR-223 in CMs. Cell size was mea- sured via surface area calculation under fl uorescence micros- copy after anti-α-actinin staining. Expression levels of ANP, α-actinin, Myh6, Myh7, as cardiac hypertrophy related marker genes, were detected by RT-PCR. The expression of TNNI3K protein was analysed by western blot. Luciferase assay was performed to confi rm the direct binding of miR-223 to the 3′UTR of TNNI3K mRNA. Results In ET-1 induced hypertrophic CMs, expression of miR-223 was lower than that in normal CMs (Normal CMs: 1.00±0.08 vs Hypertrophic CMs: 0.62±0.16, p<0.05).
    [Show full text]
  • Region of Interest Analysis Using Mass Spectrometry Imaging Of
    www.nature.com/scientificreports OPEN Region of Interest analysis using mass spectrometry imaging of mitochondrial and sarcomeric Received: 1 September 2017 Accepted: 30 April 2018 proteins in acute cardiac infarction Published: xx xx xxxx tissue Yuka Yajima1, Takuya Hiratsuka2, Yu Kakimoto3, Shuichiro Ogawa4, Keisuke Shima5, Yuzo Yamazaki5, Kenichi Yoshikawa 6, Keiji Tamaki7 & Tatsuaki Tsuruyama2 Matrix-assisted laser desorption ionization image mass spectrometry (MALDI-IMS) has been developed for the identifcation of peptides in various tissues. The MALDI-IMS signal distribution patterns and quantifcation of the signal intensities of the regions of interest (ROI) with healthy regions were compared for identifcation of the disease specifc biomarkers. We performed a new ROI analysis using the conventional t-test and data number independent Cohen’s d-value analysis. Using these techniques, we analysed heart tissues after acute myocardial infarction (AMI). As a result, IMS signals of mitochondrial adenosine triphosphate synthase alpha subunit (ATP5A), myosin-6/7(MYH6/7), aortic actin, and the myosin light chain 3 (MYL3) were identifed in the infarcted region. In particular, the signals of MYH7 are signifcantly greater in the infarcted region using ROI analysis. ROI analysis using MALDI-IMS may be a promising technique for the identifcation of biomarkers for pathological studies that involve the comparison of diseased and control areas. Imaging mass spectrometry (IMS) is a technique used to visualize the spatial distribution of chemical compo- sitions by their m/z of molecular masses (m) to electron charge (z) and measurement of (phospho) lipids and other low weight molecular drugs1–3. Over the past several decades, secondary ion mass spectrometry (SIMS) imaging mass spectrometry (SIMS-IMS) has played a pivotal role in pharmacological monitoring.
    [Show full text]
  • Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy
    Journal of Clinical Medicine Article Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy 1, 2, 3, 3 Hyung Yoon Kim y , Jong Eun Park y, Sang-Chol Lee * , Eun-Seok Jeon , Young Keun On 3, Sung Mok Kim 4 , Yeon Hyeon Choe 4 , Chang-Seok Ki 5, Jong-Won Kim 6 and Kye Hun Kim 1 1 Department of Cardiovascular Medicine, Chonnam National University Medical School/Hospital, Gwangju 61469, Korea; [email protected] (H.Y.K.); [email protected] (K.H.K.) 2 Department of Laboratory Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri 11923, Korea; [email protected] 3 Department of Internal Medicine, Cardiovascular Imaging Center, Heart, Vascular & Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] (E.-S.J.); [email protected] (Y.K.O.) 4 Department of Radiology, Cardiovascular Imaging Center, Heart, Vascular & Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] (S.M.K.); [email protected] (Y.H.C.) 5 Green Cross Genome, Yongin 16924, Korea; [email protected] 6 Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-3410-3419 These authors equally contributed to this work as co-first authors. y Received: 27 April 2020; Accepted: 27 May 2020; Published: 1 June 2020 Abstract: Background: The spectrum of genetic variants and their clinical significance of Hypertrophic cardiomyopathy (HCM) have been poorly studied in Asian patients.
    [Show full text]
  • The Use of Genetic Analyses and Functional Assays for the Interpretation of Rare Variants in Pediatric Heart Disease
    The use of genetic analyses and functional assays for the interpretation of rare variants in pediatric heart disease A dissertation submitted to the Division of Graduate Studies and Research, University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Molecular Genetics by Jeffrey A. Schubert Bachelor of Science, Mount St. Joseph University, 2012 Committee Chair: Stephanie M. Ware, M.D., Ph.D. Edmund Choi, Ph.D. Benjamin Landis, M.D. Anil Menon, Ph.D. David Wieczorek, Ph.D. Molecular Genetics, Biochemistry, and Microbiology Graduate Program College of Medicine, University of Cincinnati Cincinnati, Ohio, USA, 2018 ABSTRACT The use of next generation technologies such as whole exome sequencing (WES) has paved the way for discovering novel causes of Mendelian diseases. This has been demonstrated in pediatric heart diseases, including cardiomyopathy (CM) and familial thoracic aortic aneurysm (TAA). Each of these conditions carries a high risk of a serious cardiac event, including sudden heart failure or aortic rupture, which are often fatal. Patients with either disease can be asymptomatic before presenting with these events, which necessitates early diagnosis. Though there are many known genetic causes of disease for both conditions, there is still room for discovery of novel pathogenic genes and variants, as many patients have an undefined genetic diagnosis. WES covers the protein-coding portion of the genome, which yields a massive amount of data, though it comprises only 1% of the genome. Sorting and filtering sequencing information to identify (sometimes) a single base pair change responsible for the patient phenotype is challenging. Further, interpreting identified candidate variants must be done according to strict standards, which makes it difficult to definitively say whether a coding change is pathogenic or benign.
    [Show full text]